Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. SPCX
6. DPZ
7. NVDA
8. PRIM
9. META
10. SPY

Go back to Galectin Therapeutics Provides Phase 2 NASH Program Update and Reports Second Quarter 2015 Financial Results

Galectin Therapeutics (GALT) Reports Q2 Loss of $0.21

August 10, 2015 8:10 AM EDT

Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.21), versus ($0.17) reported last year.

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

... More